Glenmark Pharmaceuticals S.a.

Vishal Govindrao Deshmukh

Neelima Khairatkar-Joshi

Abraham Thomas

Sachin Sundarlal Chaudhari

Sukeerthi Kumar

Indranil Mukhopadhyay

Ashok Bhausaheb Kadam

Sachin Vasantrao Dhone

Nisha Parag Patil

Rajendra Prakash Chikhale

Daisy Manish Shah

Malini Bajpai

Sanjib Das

Shailesh Ramesh Pardeshi

Prashant Dilip Wadekar

Neelima Khairatkar-joshi

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X, X, M, R, R, R, R, m, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, neurodegenerative diseases and cancer. 

Bicyclic heteroaryl indole analogues useful as ROR gamma modulators

The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. 

Fused pyrimidine-dione derivatives as TRPA1 modulators

Growing community of inventors

Shrirampur, India

Vishal Govindrao Deshmukh